BOSTON, October 25, 2024 – Proskauer, a leading international law firm, announced today that it advised ARCH Venture Partners ("ARCH") on the closing of ARCH Venture Fund XIII. The fund closed with more than $3 billion in commitments and will support the founding and growth of early-stage biotechnology companies.
ARCH founds and invests in groundbreaking life science and technology companies that prevent, detect and cure disease. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories.
Proskauer has advised ARCH on several previous fund formations as part of its long-standing relationship with the firm, which dates back over 30 years. Most recently, the Firm advised on ARCH Venture Fund XII, which closed in June 2022 with $2.975 billion in commitments.
The Proskauer team was led by partners Robin Painter, David Jones and Jeremy Naylor, senior counsel Louis Sorgi and associates Tracy Rizk, Celeste Kim and Ben Swiszcz (Private Investment Funds).